GSK Adds 330,000 Shares to Treasury in Ongoing Buyback Programme

GlaxoSmithKline ( (GB:GSK) ) has issued an announcement.

GSK has continued its existing share buyback programme, repurchasing 330,000 ordinary shares on 9 April 2026 through BNP Paribas at a volume-weighted average price of 2,139.38 pence, with the shares to be held in treasury rather than cancelled. Since this phase of the programme began in February, GSK has acquired 17.9 million shares, lifting treasury holdings to about 6.35% of total voting rights and leaving 4.06 billion shares in issue, a move that tightens the free float and may enhance per-share metrics for investors.

The most recent analyst rating on (GB:GSK) stock is a Sell with a £19.00 price target. To see the full list of analyst forecasts on GlaxoSmithKline stock, see the GB:GSK Stock Forecast page.

Spark’s Take on GSK Stock

According to Spark, TipRanks’ AI Analyst, GSK is a Neutral.

The score is driven primarily by strong profitability and improving recent fundamentals, supported by constructive 2026 guidance and pipeline momentum. Valuation is reasonable with a modest yield, while the main constraint is technical overbought risk and ongoing balance-sheet/earnings-consistency considerations.

To see Spark’s full report on GSK stock, click here.

More about GlaxoSmithKline

GSK plc is a global biopharmaceutical company focused on developing and commercializing prescription medicines, vaccines and specialty therapies. Listed in London, it targets large international markets for infectious diseases, respiratory conditions and other high-burden illnesses, competing with major pharmaceutical peers for share in both primary care and specialist segments.

Average Trading Volume: 9,596,234

Technical Sentiment Signal: Buy

Current Market Cap: £84.92B

Learn more about GSK stock on TipRanks’ Stock Analysis page.